Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.250 +0.060 (+2.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
21 22 Next >
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Is Iovance Biotherapeutics Stock a Buy Now?
It will take a while for its risks to resolve. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Is Crashing Today
One of the small biotech's top pipeline programs ran into a major setback. 
Via The Motley Fool
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Opportunities for Iovance Biotherapeutics Stock, and 1 Risk
The potential pitfall could be dire, but the odds seem to be in the biotech's favor. 
Via The Motley Fool
Is Iovance Biotherapeutics a Buy Before This Key FDA Decision?
Iovance shares have dropped by double digits over the past three years. 
Via The Motley Fool
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist
These biotech innovators have what it takes to soar. 
Via The Motley Fool
What's Next for Iovance Biotherapeutics Stock?
Focusing on its clinical trial setback could mean missing the bigger picture. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
2 Growth Stocks That Could Rocket 149% to 210% Higher in 2024, According to Wall Street
Find out why investment bank analysts are hyperbullish for these stocks. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Popped Today
Iovance rebounded nicely after yesterday's drop, which came after the FDA put a clinical hold on its cancer-therapy trial. 
Via The Motley Fool
What's Going On With Bone Biologics Corp Stock?
Bone Biologics Corp (NASDAQ: BBLG) shares are trading higher Thursday and has been halted multiple times despite a lack of company-specific news. Here's what you need to know. 
Via Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
Investor Sentiment Edges Lower; Dow Jumps Over 100 Points
The CNN Money Fear and Greed index showed a decline in overall market sentiment, but the index remained in the "Extreme Greed" zone on Wednesday. U.S. stocks closed higher on Wednesday, with the Dow... 
Via Benzinga
Topics Stocks
Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Wednesday. The Dow traded up 0.05% to 37,564.54 while the NASDAQ fell 0.04% to 15,069.30. The... 
Via Benzinga
Topics Stocks
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Gold Gains 1%; Richmond Fed Manufacturing Index Falls In December
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 80 points on Wednesday. The Dow traded up 0.22% to 37,626.76 while the NASDAQ rose 0.06% to 15,084.02. The S&P... 
Via Benzinga
Topics Economy Stocks
Iovance Biotherapeutics, Nio, NetEase And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 80 points on Wednesday. 
Via Benzinga
Topics Stocks
FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient Death
Wednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non- 
Via Benzinga
US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.